

X-ray Microscopy for Inhalation Formulations


Parmesh Gajjar

Henry Moseley X-ray Imaging Facility, The University of Manchester

parmesh.gajjar@manchester.ac.uk

Hrishikesh Bale
Vivian Barron
Tim Burnett
Xizhong Chen
James Elliott
Robert Hammond
Allistair McBride

Darragh Murnane
Hien Nguyen
Kevin Roberts
Ioanna Danai Styliari
Ben Tordoff
Philip Withers




X-ray microscopy for inhalation formulations

- Recent development of x-ray magnification optics allows higher resolution and improved contrast compared to traditional x-ray computed tomography (XCT) systems
- These instruments are known as x-ray microscopes (XRM)
- A typical dry powder inhalation formulation consists of a mixture of large carrier lactose, micronized drug and micronized lactose
- Aim of this part of INFORM2020 project was to use XRM to examine the microstructure of these different parts of a dry powder inhalation formulation



The inside of a Zeiss Xradia Versa X-ray Laboratory Microscope



Main parts of a dry powder inhaler formulation: (a) Carrier lactose; (b) Micronised Drug and (c) Micronised Lactose

Characterising carrier lactose using XRM

- Microscale XRM (Zeiss Xradia Versa) has been used to characterise both tableting and inhalation grade lactose

- Work recently published in European Journal of Pharmaceutics and Biopharmaceutics


3D Characterisation of Dry Powder Inhaler Formulations:
Developing X-ray Micro Computed Tomography Approaches

Gajjar, P. et al *Eur. J. Pharm. Biopharm.* (2020)


Open Access: DOI [10.1016/j.ejpb.2020.02.013](https://doi.org/10.1016/j.ejpb.2020.02.013)

- It is possible to visualise and quantify the number of fine lactose particles $<12 \mu\text{m}$, with LH100 and LH200 containing 9426 ± 559 particles per mm^3 and 66458 ± 6033 particles per mm^3 respectively.

- High variation in LH200 may explain chaotic behaviour previously seen in experiments.




Visualisation of fine lactose present in (a) LH100 and (b) LH200





Chaotic behaviour of LH200 from [DOI:10.1016/j.ijpharm.2018.10.021](https://doi.org/10.1016/j.ijpharm.2018.10.021) showing variable behaviour between runs

Microstructure of single lactose agglomerates

- Nanoscale XRM (Zeiss Xradia Ultra) with a resolution of 150 nm allows microstructure of micronized agglomerates to be assessed. Here a LH300 agglomerate is analysed.
- Porosity within the agglomerate can be calculated as $72.1 \% \pm 0.7 \%$.
- Individual particles within the agglomerate can be separated. A intra-agglomerate size distribution is bimodal with a small peak around $0.5 \mu\text{m}$ and a second peak around $2.5 \mu\text{m}$.




(a) Single virtual cross sectional slice through agglomerate




(c) Size distribution for particles within agglomerate; (d) 3D visualisation with particles coloured by size.

Microstructure of blends

- Microscale XRM (Zeiss Xradia Versa) has been used to characterise drug-carrier blends and identify the different compounds
- This allows individual structures to be examined such as drug-carrier agglomerates, or drug adhesion to carrier facets.
- 3D information provided by XRM allows unique insight into the microstructure compared to currently employed techniques such as scanning electron microscopy (SEM).



Microstructure of an inhalation blend, with lactose coloured blue and drug orange. Inset shows a drug-lactose agglomerate with lactose coloured grey and drug coloured by thickness of layer.



(a) 3D visualisation of blend compared with current standard method of using an SEM (b).

Thanks to ...

MANCHESTER
1824
The University of Manchester



Parmesh Gajjar

Philip Withers

Timothy Burnett

University of
Hertfordshire **UH**



Ioanna Danai
Styliari

Darragh
Murnane

UNIVERSITY OF
CAMBRIDGE



Xizhong Chen

James Elliott

UNIVERSITY OF LEEDS



Hien Nguyen

Vivian Barron

Kevin Roberts

Robert Hammond

ZEISS



Hrishikesh Bale

Ben Tordoff

Allister McBride

UKRI Engineering and
Physical Sciences
Research Council
Grant EP/N025075/1

3M
Drug Delivery Systems Division

AstraZeneca

gsk

ZEISS

Malvern
Analytical

Intertek MELBOURN scientific

nanopharm

neutec

DFE pharma

team. medical design and development